Introduction
Carcinogenesis is a multifactorial, multistep process. Mutations in proto-oncogenes and tumor suppressor genes, gene amplifications and deletions, and translocations resulting in fusion proteins have all been well described to contribute to carcinogenesis. In this regard, cancer is a genetic disease. However, epigenetic mechanisms have also long been known to contribute to oncogenic transformation. It is interesting to note that the exact definition of epigenetics is still a matter of conjecture; for practical purposes the following definition is useful: 'Nuclear inheritance which is not based on changes in DNA sequence'. 1 Recent years have seen substantial progress in the area of epigenetic gene regulation, with implications for the understanding of diverse topics such as normal cell physiology, stem cell pluripotency and tumor growth.
Epigenetics is affected by multiple different mechanisms
The correlation between DNA methylation and gene silencing has been appreciated for decades, and its role in cancer research was started being appreciated in the early 1980s.
2 DNA methylation was the first known epigenetic mechanism and is the best understood. DNA methylation in mammals occurs in the carbon 5 position of the cytosine ring, in the context of CpG dinucleotides. It is catalyzed by S-adenosyl methionine-dependent DNA methyltransferases (DNMTases, DNMT1, DNMT3A, DNMT3B). Homozygous deletion of Dnmt1 is embryonic lethal in mice, suggesting an important role in developmental gene regulation, 3 and loss of DNA methylation has been correlated with genetic instability. 4 In total, 70-80% of CpG dinucleotides are typically methylated in the mammalian genome. This dinucleotide occurs with only 10% of the predicted frequency, as methylcytosine is easily deaminated to thymine. It is interesting to note that this mechanism has been shown to lead to point mutations in genes such as TP53. 5 The unmethylated CpG dinucleotides are typically located in so-called CpG islands, regions with a high CG content, which occur typically in promoters. Of note, many genes carry no CpG islands in their promoters. Cancer cells show aberrant DNA methylation. Their genome is typically globally hypomethylated, an alteration thought to be acquired early in the course of carcinogenesis. 6 Cancer cells also show local hypermethylation, which in promoters containing CpG island correlates with silenced expression, (reviewed in 7 ) . The role of differential methylation in non-cancerous tissues, and at promoter sites without CpG islands is less clear, but is beginning to be assessed. 8, 9 Recent years have witnessed genome-wide methylation maps, with different levels of resolution on the basis of the corresponding technology employed (reviewed in 10 ). Genome-wide DNA methylation studies have been published for solid tumors such as lung cancer, 11, 12 and for leukemias. AML cell lines 13 and primary samples have been studied, and in one study relapse was associated with increased methylation of CpG islands. 14 ALL cell lines and patient samples were also evaluated. 15, 16 It is not completely understood how specific genes are targeted in cancer for de novo methylation. Chromosomal clustering and sequence analysis of methylation sites suggest a non-random mechanism; 17 furthermore, oncogenic fusion protein recruitment of DNMT1 has been documented for PML-RARa in PML. 18 There is also emerging data supporting an interplay between histone-modifying enzyme complexes and DNA methylation (see below).
Histone acetylation was noted to be associated with transcriptionally active chromatin in the 1960s. 19 The net level of acetylation is regulated by a balance between histone acetylation and deacetylation, catalyzed by histone acetyl transferases (HATs) from one of the three families (GNAT, MYST and p300/CBP), and histone deacetylases (HDACs), again from one of the three families (Type I, IIa and b and III (Sirtuins)). Histone acetyl transferases are involved in the generation of chromatin structure conducive to transcription. HDACs are believed to be involved in gene repression. It is interesting to note that their pharmacological inhibition leads to both, up-or downregulation of a number of genes, 20, 21 perhaps through mechanisms that indirectly modulate gene expression.
Other mechanisms of epigenetic gene regulation exist, and they often converge with other cellular functions such as DNA replication and DNA-damage response: chromatin-remodeling factors influence nucleosome positioning and gene regulation. For example, INI1/SNF5 is part of the SWI/SNF ATP-dependent DNA-remodeling complex. Inactivating mutations in a pediatric cancer, rhabdoid tumor, have been described, and mice with a conditional reversibly invertible Snf5 allele develop rhabdoid tumors and frequent T-cell neoplasms. 22 DNA-remodeling complexes have recently been reviewed. 23 Alternative histones (such as H2AZ, H2AX and H3.3) comprise another layer of regulation. They are deposited in areas of DNA damage, and are involved in gene regulation. More recent data suggest a role in the regulation of pluripotency. 24 This topic has recently been reviewed. 25 However, the role of alternative histones in malignant cell growth is just beginning to be interrogated.
There is also growing appreciation of the role of RNA in gene regulation. Micro RNAs impact on hematopoiesis and leukemia via posttranscriptional mechanisms. 26 Newer data suggest that RNAs can recruit polycomb proteins to their target sites, at least, in the case of X-chromosome inactivation mediated by the ncRNA XIST, 27 and in the case of Hox gene regulation by the ncRNA HOTAIR. 28 As the density of transcribed RNAs in the genome seems to be much higher than appreciated earlier, 29 it is tempting to speculate that ncRNA-based mechanisms beyond miRNAs play a role in cancer and leukemia.
Two aspects make the study of epigenetic gene regulation relevant for cancer research: First, a better understanding of epigenetic gene regulation will further our understanding of how cells are transformed. Second, epigenetic marks are in principle reversible, as opposed to, for example, gene deletions. This in principle makes it possible to counteract tumor-specific epigenetic changes. This, in turn, would hopefully result in cancer cell death or differentiation. Many epigenetic changes are affected by enzymes, which are traditionally considered amenable to antagonism through small molecule inhibitors, and thus presumably are viable candidates as drug targets. Successful pharmacological reversal of DNA methylation has led to the proof of concept for epigenetic therapy of cancer. DNA demethylating agents lead to reexpression of silenced genes, 30, 31 and have found applications in non-malignant disease such as sickle cell disease, as well as in cancer. Two agents are FDA approved, 5-Aza Cytidine and 5-Aza-2-deoxyCytidine. These agents have been used with promising results in acute leukemia and myelodysplastic syndromes. The clinical results using these drugs for the treatment of myeloid malignancies have recently been reviewed, 32 and will not be discussed in detail here. The second example for successful epigenetic cancer therapy is the clinical development of the HDAC inhibitor suberoylanilide hydroxamic acid, which has recently been approved for the treatment of cutaneous T-cell lymphoma. 33 Other compounds are being studied in the lab and in clinical trials, and the incorporation of HDAC inhibitors into cancer treatment regimens is an active field of study. 34 An emerging theme is the role of covalent chromatin modifications and the central role they play in the regulation of transcription, the differentiation of cells and the development of malignancy. 35, 36 It is important to note that genes encoding chromatin-modifying enzymes are frequent translocation partners of oncogenic fusion proteins in leukemia (for example, 'MLL1/ALL1', encoding an H3K4 methyltransferase or the genes for the acetyltransferases CBP, p300 and 'MOZ/MYST3'), supporting the concept that chromatin modification plays an important role in leukemogenesis.
Several histone modifications have been described, including acetylation (see above), lysine methylation, arginine methylation, phosphorylation, ubiquitination, sumoylation, ADP ribosylation, deimination and proline isomerization. They generally function in two ways. First, they influence chromatin packaging, and thus affect looser or more tightly packaged chromatin structure, indirectly regulating transcription. Second, they serve as docking sites for other protein complexes such as chromatin-remodeling complexes, DNA methylases and other enzymatic modifiers of histones (reviewed in 36 ). Here, we want to discuss recent progress in the area of genome-wide characterization of chromatin and specifically histone methylation, with a focus on how they relate to leukemia.
Histone methylation
Histone methylation was described over 40 years ago. The actual enzymes responsible for histone methylation were reported much later, starting in the mid 1990s (reviewed in Zhang and Reinberg 37 ). Histones can be modified on arginine and lysine residues. We will briefly describe the most common histone methyl marks and then review recent genome-wide studies, focusing mostly on histone lysine methylation. Nomenclature is used, in which the first letter (H) stands for 'histone', the second character indicates which histone is referred to (followed by 'A' or 'B' in the case of histone 2A or 2B), the third character indicates which amino acid is modified and the fourth character (and additional characters for a number 49) refers to the position of the amino acid in the protein. The lower-case letters 'me' refer to methylation, and the number following 'me' refers to the number of methyl groups added, typically 1-3. For example, H3K27me3 indicates trimethylation of a lysine residue in position 27 of the histone 3 protein.
H3K9 methylation
The so-called SET domain is characteristic of histone lysine methyl transferases, and was described in Su(var)3-9, Enhancer of zeste and Trithorax (that is, the name is an acronym). This domain is present in all histone lysine methyltransferases, with the exception of Dot1 (see below). The discovery that 'SUV39 ', the mammalian homolog to Drosophila Su(var)3-9, encodes a histone methyltransferase 38 that tri-methylates histone 3 on lysine 9 (H3K9me3) was an important step ahead for the field of epigenetics and chromatin research. This enzyme is involved in the generation of heterochromatin. The ensuing H3K9 trimethyl mark recruits HP1. [39] [40] [41] Other enzymes can methylate H3K9, for example, G9a. G9a seem to predominantly place H3K9me2 marks in euchromatin, whereas Suv39 seems to mostly place H3K9me3 marks in pericentric heterochromatin. H3K9me2 and H3K9me3 marks, in a region of 10 kb upstream and downstream of the transcription start site, have been reported to be mostly, but not uniformly, associated with gene silencing. 42 It is interesting to note that SUV39 seems to be involved in senescence in vivo, which seems to constitute a barrier to cancer development. In a mouse model of ras-driven malignancy, targeted deletion of Suv39 led to lymphoma development, as opposed to delayed onset non-lymphoid tumors in Suv39 expressing mice. 43 
H3K36 methylation
This histone modification is found in the gene body rather than in promoter regions, and tri-methylation is associated with active transcription. 42, 44 The first H3K36 methylase described was Set2 45 
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SETD2. 48 H3K36 methyltransferase activity has also been suggested for ASH1. 49 NSD1 is of particular interest as it is involved in a leukemogenic translocation that depends on enzymatic activity of the methyltransferase domain.
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H3K4 methylation
After the showing that the SET domain containing protein SUV39 is a histone methyltransferase, other SET domain containing proteins were scrutinized. The yeast protein Set1 was found to show homology to human MLL and was shown to be part of a multiprotein complex termed COMPASS. 51 Histone methyltransferase activity for Set1 has been shown. [52] [53] [54] [55] The SET domain containing drosophila trithorax homolog MLL1 (mixed lineage leukemia), also known as ALL1, was shown to be a H3K4 methyltransferase in 2002. 56, 57 The ensuing chromatin mark is generally associated with active genes, or genes primed for expression. 42, 58, 59 Chromosomal translocations involving the MLL1 gene are found in infant leukemias in over 70% of cases, and predict a poor prognosis. They are also a hallmark of secondary leukemia arising after etoposide treatment. Expression array studies have shown that MLL-rearranged leukemias are different from both ALL and AML, 60 suggesting a unique mechanism of cellular transformation. The MLL gene was cloned in the early 1990s. 61, 62 The human gene encoding the wild-type MLL protein is located on chromosome band 11q23. Wild-type MLL contains a SET domain and exists in a large multi-protein complex. 56 Association with other proteins, including members of the polycomb family, have been described. 63 More recent data show association with the MYST-family HAT MOF. 64 Over 50 different translocation partners have been described, but the exact mechanism of transformation is not well understood on a mechanistic level. It is also not known if all MLL-fusion genes act by the same mechanism (see below). In the leukemogenic chromosomal rearrangements (with the exception of the partial tandem duplication (PTD), which also lack the specific gene expression profile of other MLL-translocated leukemias, 65 the SET domain is invariably lost.
H3K27 methylation
H3K27 trimethylation is believed to be a repressive chromatin mark and is catalyzed by EZH2 in complex with other components of the polycomb repressive complex 2 (PRC2). 66, 67 Polycomb genes were originally discovered as mutations that give rise to ectopic sex combs in Drosophila males. It has been shown that they are important for the epigenetically inherited maintenance of orderly Hox gene expression during development (reviewed in 68 ). Recent genome-wide studies in embryonic stem cells and other cell types have suggested a more generalized role for polycomb complexes in the maintenance of pluripotency and cellular differentiation (see below). PRC2 is also required for X-chromosome inactivation. Finally, very recent data suggest a role in imprinting. 69, 70 In drosophila, PRC2 binds specific polycomb response elements. It is less clear how PRC2 is recruited in higher species. Recent data suggest that non-coding RNA may be involvedFHOTAIR 28 Fin the case of Hox loci, XIST in the case of X-chromosome inactivation, 27 and Kcnq1ot1 in the case of imprinting. 69, 70 Genome-wide studies suggest that H3K27me3 may also mark developmental genes for future expression by participating in a 'bivalent domain' that carries both a repressive H3K27me3 mark and an activating H3K4me3 mark. 59 Evidence exists that H3K27me3 serves as a docking site for polycomb repressive complex 1 (PRC1), 71 a multiprotein complex that among other targets, mono-ubiquitinates H2A at K119. 72, 73 However, trypsin digestion of histone tails does not interfere with PRC1-mediated chromatin compaction. 74 Furthermore, not all PRC2-binding sites are co-occupied by PRC1. 75 These latter data suggest that recruitment of PRC1 to target sites has additional layers of regulation. The study of polycomb complexes is pertinent to leukemia research, in that HOX genes play important roles in several leukemias, including MLLrearranged leukemias and AML. Polycomb proteins regulate HOX gene expression, and it is therefore reasonable to hypothesize that they play a role in leukemogenesis. Direct evidence for this hypothesis is starting to accumulate. The PMLRARAa fusion protein characteristic of promyelocyte leukemia was recently shown to bind and recruit EZH2, the catalytic component of the PRC2 complex. 76 Overexpression of PRC1 complex components, such as BMI1, has been correlated with adverse outcomes in several hematopoietic malignancies. [77] [78] [79] [80] [81] [82] However, little is known about the actual mechanisms involved, but with the advent of genome-wide studies this is likely to change in the near future.
H3K79
H3K79 methylation is mediated by DOT1L, the only known histone methyltransferase without SET domain. Dot1 was originally discovered in yeast as a gene involved in telomericassociated gene silencing. 83, 84 DOT1L binds the leukemogenic MLL-AF10 and MLL-ENL fusion proteins and indirect evidence suggests that DOT1L catalytic activity is required for transformation by these fusions. 85, 86 Furthermore, DOT1L is found in nuclear complexes with AF10, ENL, and other MLL translocation partners AF4 and AF9. 85, [87] [88] [89] [90] Ectopically expressed MLL-AF10, or a synthetic, not naturally occurring MLL-DOT1 fusion, was shown to localize to the HOXA9 locus and increase K79 methylation. This corresponded to increased HOXA9 expression, consistent with the notion that H3K79 methylation is an activating chromatin modification.
91,92
H4K20
H4K20me1 is catalyzed by the histone methyltransferase PRSET7. 93, 94 It has been linked with transcriptional repression, as well as with actively transcribed genes. H4K20me2 may play a role in DNA repair. 95 H4K20me3 is catalyzed by SUV420H1 and SUV420H2, and has a role in the generation of pericentric heterochromatin. 96 A role for H4K20 in hematological malignancy is suggested by a recent report as MMSET, a gene overexpressed in an aggressive subset of multiple myeloma carrying a t(4;14), has H4K20 histone trimethylase activity. 97 
Histone lysine demethylases
Histone methylation was considered irreversible until recently. However, the discovery of histone lysine demethylases has added another level of complexity to the regulation of chromatin structure. Lysine-specific demethylase 1 (LSD1) was the first in this class of enzymes to be reported. 98 It is interesting to note that LSD1 has an oxidative mechanism of catalysis. 98 It has also become clear that a large group of cousins of the Jumonji protein (which to the current knowledge is not a histone demethylase) function as histone demethylases, both for lysine and arginine residues (reviewed in 99 ). Some of these have been implicated in cellular transformation, 100 and growth and
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Chromatin maps, histone modifications and leukemia T Neff and SA Armstrong development of hematopoietic cells. 101 The existence of histone demethylases implies that histone modification is a dynamic process. However, understanding the kinetics of covalent histone marks is in the early stages, and whether and how they are altered in cancer and specifically in leukemia is mostly unknown.
Genome-wide studies
The completion of the human genome project, the advent of array technology and, more recently, massive parallel sequencing technology have led to a growing number of genome-wide studies. Initial chromatin immunoprecipitation-expression array ('ChIP-Chip') studies were carried out on DNA-binding proteins in yeast. 102, 103 Soon studies in mammalian cells and specifically in lymphoma followed. 104 Embryonic stem cells have received special attention, as they provide an unlimited source of totipotent cells. A recent study analyzed binding sites for transcription factors important for maintenance of pluripotency in murine embryonic stem cells, 105 and found co-occupancy at many promoter sites, suggesting cooperative action. Later studies investigated the binding of polycomb complexes in human 106 and murine 107 embryonic stem cells, and in neuronal cells and embryonic fibroblasts. 108 These studies yielded several novel insights, namely the preferential binding of polycomb group genes to developmentally important genes including those encoding several Hox, Pou and Pax transcription factors, among others. A growing number of studies focus on genomewide analysis of covalent chromatin modifications. In embryonic stem cells, maps for H3K4 and H3K27 methylation [109] [110] [111] showed a coexistence of both marks at the loci of many genes (in large part overlapping with polycomb targets). It has been postulated that this 'bivalent domain' is characteristic of stem cells. 59 A similar chromatin structure may not be uncommon in certain mature cells such as CD4-positive T lymphocytes. 42 Very recently, two classes of bivalent domains were proposed on the basis of binding of PRC1 or the absence thereof. 112 Genomewide chromatin-binding studies also suggest the presence of RNA polymerase II at a much larger number of promoters than anticipated on the basis of the level of RNA transcripts or H3K36 methylation, suggesting a role for control of elongation in the fine tuning of transcription levels. This phenomenon was observed in T cells, as well as in embryonic stem cells. 42, 113 It will be important to analyze the epigenomics of somatic stem cells. Limited data is available to this point, but studies are beginning to emerge. 114 In particular, little data concerning genome-wide analysis are published, which derives from the difficulty of isolating homogenous stem cell populations, especially, in the numbers required for genome-wide chromatin maps. Very recently, a genome-wide analysis of RNA expression, eight different chromatin marks, a variant histone (H2A.Z), and RNA polymerase II occupancy has been published for human hematopoietic CD133-positive stem/progenitor cells and CD36 erythroid cells, 115 which provides initial insight into the chromatin status of these cells. Similar studies should be carried out for murine stem cells, multipotent progenitors, and more lineage restricted progenitor cells, as more well-defined populations can be isolated. Furthermore, the intermediate differentiation steps between stem cells and cells fully committed to a single lineage are better defined in mouse than in the human. Chromatin maps will be even more informative as the ability to purify human stem cells improves.
Given the importance of epigenomic gene regulation for carcinogenesis, it is tempting to speculate chromatin modifications can distinguish different cancers, and can possibly even predict treatment response. There is also hope that some chromatin modifications may present targets for pharmacological intervention. Recently, genome-wide studies of histone modifications in cancer have been initiated to better characterize the chromatin of malignant cells. Several labs reported that H3K27 targets loci for de novo DNA methylation in cancer cells. [116] [117] [118] Silencing of genes marked by H3K27 in the absence of DNA methylation has also been reported, 119 so that the relation between H3K27me3 and DNA methylation remains an active area of study.
Few studies are published reporting genome-wide chromatin maps in leukemia. One study investigated two Philadelphia chromosome positive cases of ALL and three cases of AML, one with the t(8;21) translocation and two with normal karyotype. 120 Gene expression array analysis was combined with genomic analysis of the activating histone acetylation of H3K9 by ChIPChip and genome-wide DNA methylation analysis. Combined analysis of H3K9 acetylation and gene expression array identified additional differentially expressed genes, and functional gene sets that would have been missed with a less comprehensive analysis. The molecular heterogeneity of the samples makes it hard to draw generalizable conclusions; however, this was a proof of concept study and follow-up studies with a larger number of genetically defined leukemias will likely lead to mechanistic insights. Very recently, the direct downstream targets of an MLL-fusion, MLL-AF4, have been characterized in a genome-wide study. It is interesting to note that far fewer genomic regions are bound by the fusion than by wild-type MLL, and these regions undergo widespread (5-100 kb) chromatin remodeling with associated H3K79me2 histone marks. The bound loci include many developmental regulators (for example, HOXA9, RUNX1, and ETV6, TWIST1 and RUNX2).
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To analyze chromatin structure in MLL-rearranged leukemia, our group analyzed MLL-AF4-induced leukemia in a murine knock-in model. 122 We showed increased H3K79me2 across much of the HoxA9 cluster, a known MLL-AF4 downstream target. Genome-wide analysis by ChIP-Chip showed increased H3K79me2 associated with 1186 promoters in leukemia cells compared with normal pre-B cells. Only 285 promoters had lower levels of H3K79me2 in leukemia cells compared with normal pre-B cells. We confirmed that this epigenetic mark is associated with active transcription. Extension of these studies to human samples (comparing MLL-rearranged ALL versus nontransformed B-cell precursors) showed very similar results. A total of 369 genes were found to show increased H3K79me2 in both murine and human cells. It is interesting to note that H3K79me2-based clustering allows for distinction of MLL germline ALL versus MLL-rearranged ALL (Figure 1 ). It seems that misguided recruitment of DOT1L and subsequent aberrant gene activation by resulting H3K79 methyl marks is an important step in the leukemogenesis induced by MLL-AF4. Several other nuclear proteins, including AF10, ENL and AF9, are reported to directly or indirectly associate with Dot1. Presumably the corresponding MLL translocations also transform cells by recruiting Dot1 to ectopic loci, although this still needs to be formally shown. Of note, these fusions seem to cause transformation at least in part by gene activation, in contrast to the usual gene repression believed to be associated with epigenetic mechanisms in cancer. There are MLL fusion partners from different gene classes. Broadly, they include genes encoding cytoplasmatic proteins containing a coiled-coil domain (GAS7, EEN, AF1p, EPS15 and AF6), septins (SEPT2, SEPT5, SEPT6, SEPT9 and SEPT11) and histone acetyl transferases (CBP and p300). It will be interesting to analyze cells
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Chromatin maps, histone modifications and leukemia T Neff and SA Armstrong transformed by MLL translocations with fusion partners that presumably do not recruit DOT1L. This should be addressed by biochemical analysis of protein complexes, and by genomewide chromatin maps. In the case of the cytoplasmatic MLL translocation partner EEN, histone arginine methylation catalyzed by PRMT1 has been shown to be critically important for transformation. 123 It may be that even the molecularly defined group of MLL-rearranged leukemias will undergo further subdivision. An important future goal will be to establish chromatin maps for leukemia propagating (stem) cells. 124 We predict that these strategies will be helpful in identifying pathways critical for the 'stemness' of such cells, and give clues towards new therapeutic targets.
Epigenetic therapy is a promising concept, in part, because many players in chromatin modification and remodeling are enzymes, which traditionally make for better drug targets than, for example, transcription factors. A potential target for therapeutic intervention in cancer and leukemia may be EZH2, a core component of the PRC2 complex. An inhibitor has been described recently. 125 In these studies, some genes underwent PRC2 repression without associated DNA methylation (as described independently in Kondo et al 119 ). Some of the genes repressed contained H3K27me3 marks and were DNA methylated. Genes 'doubly repressed' could in this report be reactivated by the EZH2 inhibitor, but not inhibitors of DNMTs, arguing that there is room for 'new kids on the block' in epigenetic therapy. Issues to be resolved include questions regarding the specificity of the compound and the exact mechanism of action. These issues will undoubtfully be addressed in the near future. Of note, proof of principle for a more specific small molecule inhibitor of a methyltransferase (G9a) has recently been published. 126 The hope is that chemical modification of this molecule could lead to small molecule inhibitors of the other histone methyltransferases, akin to the large number of kinase inhibitors developed after imatinib was successfully introduced into the clinic. 127 
Outlook
The exponential growth of knowledge in the field of gene regulation has dramatically furthered our understanding of normal and malignant cell growth. 'Omic' studies are beginning to provide data in a breadth not possible earlier. Epigenetic alterations are known to be involved in carcinogenesis, and DNMT inhibitors and HDAC inhibitors have become established as active chemotherapy drugs in the treatment of hematopoietic malignancies (reviewed in Bhalla 128 ). The recent years have witnessed tremendous progress in the field of chromatin structure/dynamics and gene regulation, and an impressive number of enzymatic players have been identified in a short time period. Optimism seems justified that some of these will be identified as valid drug targets for specific cancers. Rigorous application of genomic, genetic and biochemical studies is likely to further our insight into disease mechanisms and provide new diagnostic tools. The coming years promise to be quite exciting in terms of new biological understanding and hopefully new therapeutic interventions.
